Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’ time by adding more cost-effective and highly effective dosage forms to their strong product portfolio.
Can you briefly introduce your background to our international readers and tell us a bit about the evolution of Entod?
"As a company we invest in the manufacturing side of the business quite significantly, as well as in the product development and in the regulatory sphere."
